Atricure lassoes Sentreheart for $40m
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Ablative Solutions has a fight on its hands in renal denervation
Alcohol kills – and in this case, that could be a good thing.
$1bn Corindus deal gets Healthineers off the acquisition blocks
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Bluerock unlikely to smooth Bayer’s rocky road
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Novartis’s Paragon falls short of perfection
Trying a different primary endpoint did not help Entresto in heart failure with preserved ejection fraction, but Novartis seemingly still sees a path forward.
Novartis needs new launches to keep up momentum
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Medicines Company goes on the hunt for heartening Orion data
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Upcoming events – Novartis and Miragen hope for heartening data
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
FDA adcom to pronounce on paclitaxel-coated devices
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.